D.E. Shaw & Co
HLVX

D.E. Shaw & Co’s HilleVax HLVX Stock Holding History

D.E. Shaw & Co’s Portfolio HLVX Stock Details HLVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-66,079
Closed -$956K – 4676
2024
Q2 		$956K Buy
66,079
+37,920
+135% +$521K ﹤0.01% 3233
2024
Q1 		$468K Buy
+28,159
New +$450K ﹤0.01% 3515

Other funds holding HLVX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

D.E. Shaw & Co's HLVX Position: Q3 2024 in Review

D.E. Shaw & Co sold out of HilleVax (HLVX) in Q3 2024, closing a stake of 66,079 shares — an estimated $956K sold.

D.E. Shaw & Co first reported a position in HLVX in Q1 2024 and held it in 2 quarters. The position peaked at $956K in Q2 2024. 79 funds tracked by Wall St. Rank hold HLVX as of Q3 2024.

  • D.E. Shaw & Co reported no remaining HilleVax position as of Q3 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 66,079 HilleVax shares in Q3 2024, an estimated $956K.
  • D.E. Shaw & Co first reported a position in HilleVax in Q1 2024 and held it in 2 quarters.
  • D.E. Shaw & Co's HilleVax position peaked at $956K in Q2 2024.
  • 79 funds tracked by Wall St. Rank held HilleVax as of Q3 2024.

Based on D.E. Shaw & Co's 13F filing for Q3 2024, filed 14 Nov 2024.